Sign In

Antiretroviral Therapy.

HIV Question Bank

Adverse Effects of Antiretroviral MedicationsQuestion 3/10

Questions in Topic

A 37-year-old cisgender man with HIV and a CD4 count of 574 cells/mm3 has taken atazanavir-cobicistat and tenofovir DF-emtricitabine for about 6 years. Laboratory studies 6 months ago showed a total bilirubin level of 2.5 mg/dL. At a current clinic visit, scleral icterus is noted on physical examination and laboratory studies show a total bilirubin level of 3.8 mg/dL. He states that he feels well and has no other symptoms.

Which one of the following is the most likely cause of his jaundice?

Atazanavir can increase serum total bilirubin through inhibition of the liver enzyme uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1); this enzyme is a key enzyme in the normal glucuronidation of bilirubin.<br /> Abbreviation: UGT1A1 = uridine diphosphate glucuronosyltransferase 1A1
Figure 1. Atazanavir and Inhibition of the UGT1A1 Enzyme.
Atazanavir can increase serum total bilirubin through inhibition of the liver enzyme uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1); this enzyme is a key enzyme in the normal glucuronidation of bilirubin.
Abbreviation: UGT1A1 = uridine diphosphate glucuronosyltransferase 1A1
Illustration: David H. Spach, MD
Prev  Skip

Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Question Last Updated
July 27th, 2024

Steps to Acquire CE for this Question Bank Topic:

1

Answer

Answer all questions
2

Score 80%+

Answer correctly
3

Claim CE

Choose CNE or CME
4

Give Feedback

Complete survey
5

Print Certificate

Obtain proof of CE

This question requires improvement because:


Comment further on how to improve this question or summary:



Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.